Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4

Immunological Reviews

Volumn 202, Issue , 2004, Pages 139-156

  Watford, Wendy T ^a   Hissong, Bruce D ^a   Bream, Jay H ^b   Kanno, Yuka ^a   Muul, Linda ^a   O'Shea, John J ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD4 ANTIGEN; CURCUMIN; CYTOKINE ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12 BETA1 RECEPTOR; INTERLEUKIN 12 BETA2 RECEPTOR; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 23; JANUS KINASE; JANUS KINASE 2; LISOFYLLINE; MEVALONIC ACID; PEPTIDE DERIVATIVE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RECEPTOR SUBUNIT; SMALL INTERFERING RNA; STAT PROTEIN; STAT4 PROTEIN; STATINE DERIVATIVE; SUPPRESSOR OF CYTOKINE SIGNALING; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG TARGETING; ENTERITIS; ENZYME ACTIVATION; GENE CONTROL; GENE INDUCTION; GENE TARGETING; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; SIGNAL TRANSDUCTION; STAT4 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 9644257195     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00211.x     Document Type: Review

References (267)

1. Gately MK, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-882.
2. Gubler U, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143-4147.
3. Wolf SF, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-3081.
4. Trinchieri G, Scott P. Interleukin-12: a proinflamrnatory cytokine with immunoregulatory functions. Res Immunol 1995;146:423-431.
5. Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999;238:57-78.
6. Esche C, Shurin MR, Lotze MT. IL-12. In: Oppenheim JJ, Feldmann M, eds. Cytokine Reference. San Diego: Academic Press, 2000:189-201.
7. Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 1992;13:77-78.
8. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
9. Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002;14:380-383.
10. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680.
11. Scanga CA, et al. Cutting edge: MyD88 is required for resistance to Toxoplosma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002;168:5997-6001.
12. Jacobson NG, et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat) 3 and Stat4. J Exp Med 1995;181:1755-1762.
13. Cella M, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-752.
14. Ma X, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996;183:147-157.
15. Yoshida A, et al. IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun 1994;198:857-861.
16. Kubin M, Chow JM, Trinchieri G. Differential regulation of interleukin-12 (IL-12), tumor necrosis factor alpha, and IL-1 beta production in human myeloid leukemia cell lines and peripheral blood mononuclear cells. Blood 1994;83:1847-1855.
17. D'Andrea A, et al. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med 1995;181:537-546.
18. Takenaka H, et al. Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4. J Leukoc Biol 1997;61:80-87.
19. Hochrein H, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000;192:823-833.
20. Marshall JD, et al. Priming with IL-4 and IL-13 during HIV-1 infection restores in vitro IL-12 production by mononuclear cells of HIV-infected patients. J Immunol 1997;159:5705-5714.
21. Major J, Fletcher JE, Hamilton TA. IL-4 pretreatment selectively enhances cytokine and chemokine production in lipopolysaccharide-stimulated mouse peritoneal macrophages. J Immunol 2002;168:2456-2463.
22. Koch F, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 1996;184:741-746.
23. Snijders A, et al. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol 1996;156:1207-1212.
24. Schindler H, et al. The production of IFN-gamma by IL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J Immunol 2001;166:3075-3082.
25. Aliberti J, Sher A. Positive and negative regulation of pathogen induced dendritic cell function by G-protein coupled receptors. Mol Immunol 2002;38:891-893.
26. Cong Y, Oliver AO, Elson CO. Effects of cholera toxin on macrophage production of co-stimulatory cytokines. Eur J Immunol 2001;31:64-71.
27. Fugier-Vivier I, et al. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 1997;186:813-823.
28. Murphy TL, et al. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol 1995;15:5258-5267.
29. Ma X, et al. Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J Biol Chem 1997;272:10389-10395.
30. Plevy SE, et al. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol 1997;17:4572-4588.
31. Wang IM, et al. An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages. J Immunol 2000;165:271-279.
32. Sanjabi S, et al. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA 2000;97:12705-12710.
33. Gri G, et al. Synergistic regulation of the human interleukin-12 p40 promoter by NFkappaB and Ets transcription factors in Epstein-Barr virus-transformed B cells and macrophages. J Biol Chem 1998;273:6431-6438.
34. Zhu C, et al. Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP. J Biol Chem 2003;278:39372- 39382.
35. Salkowski CA, et al. IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. J Immunol 1999;163:1529-I536.
36. Giese NA, et al. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med 1997;186:1535-1546.
37. Scharton-Kersten T, et al. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J Exp Med 1997;186:1523-1534.
38. Liu J, et al. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and Interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J Exp Med 2003;198:1265-1276.
39. Babik JM, et al. Expression of murine IL-12 is regulated by translational control of the p35 subunit. J Immunol 1999;162:4069-4078.
40. Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-725.
41. Lee E, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-130.
42. Pirhonen J, Matikainen S, Julkunen I. Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 2002;169:5673-5678.
43. van Seventer JM, Nagai T, van Seventer GA. Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells. J Neuroimmunol 2002;133:60-71.
44. Chua AO, et al. Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp13O. J Immunol 1994;153:128-136.
45. Chua AO, et al. Cloning and characterization of a mouse IL-12 receptor-beta component. J Immunol 1995;155:4286-4294.
46. Presky DH, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996;93:14002-14007.
47. Esche C, Shurin MR, Lotze MT. IL-12 receptor. In: Oppenheim JJ, Feldmann M, eds. Cytokine Reference. San Diego: Academic Press, 2000.
48. Grohmann U, et al. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 1998;9:315-323.
49. Desai BB, et al. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992;148:3125-3132.
50. Szabo SJ, et al. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med 1997;185:817-824.
51. Lighvani AA, et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001;98:15137-15142.
52. + T cells. Nat Immunol 2002;3:549-557.
53. Rogge L, et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997;185:825-831.
54. Sinigaglia F, et al. Regulation of the IL-12/IL-12R axis: a critical step in T-helper cell differentiation and effector function. Immunol Rev 1999;170:65-72.
55. Parham C, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002;168:5699-5708.
56. Belladonna ML, et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002;168:5448-5454.
57. Bacon CM, et al. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995;181:399-404.
58. Zou J, et al. Differential associations between the cytoplasmic regions of the interleukin-12 receptor subunits beta1 and beta2 and JAK kinases. J Biol Chem 1997;272:6073-6077.
59. Karaghiosoff M, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000;13:549-560.
60. Neubauer H, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397-409.
61. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
62. Bacon CM, et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA 1995;92:7307-7311.
63. Yamamoto K, et al. Stat4, a novel gamma Interferon activation site-binding protein expressed in early myeloid differentiation. Mol Cell Biol 1994;14:4342-4349.
64. Zhong Z, Wen Z, Darnell JE Jr. Stat3 and Stat4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA 1994;91:4806-4810.
65. Naeger LK, et al. Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling. J Biol Chem 1999;274:1875-1878.
66. Wu C, et al. IL-12 receptor beta 2 (IL-12R beta 2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. J Immunol 2000;165:6221-6228.
67. Szabo SJ, et al. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling. Immunity 1995;2:665-675.
68. Nishikomori R, et al. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12Rbeta2 chain expression and signaling. J Immunol 2002;169:4388-4398.
69. Usui T, et al. GATA-3 suppresses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. Immunity 2003;18:415-428.
70. Frucht DM, et al. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001;22:556-560.
71. Ota N, et al. N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat Immunol 2004;5:208-215.
72. Murphy TL, et al. Role of the Stat4 N domain in receptor proximal tyrosine phosphorylation. Mol Cell Biol 2000;20:7121-7131.
73. Chang HC, et al. STAT4 requires the N-terminal domain for efficient phosphorylation. J Biol Chem 2003;278:32471-32477.
74. Maritano D, et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 2004;5:401-409.
75. Hoey T, et al. Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses. EMBO J 2003;22:4237-4248.
76. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000;19:2628-2637.
77. Varinou L, et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 2003;19:793-802.
78. Shen Y, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 2004;24:407-419.
79. Visconti R, et al. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood 2000;96:1844-1852.
80. Morinobu A, et al. STAT4 serine phosphorylation is critical for IL-I2-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 2002;99:12281-12286.
81. Yu CR, et al. Differential utilization of Janus kinase-signal transducer activator of transcription signaling pathways in the stimulation of human natural killer cells by IL-2, IL-12, and IFN-alpha. J Immunol 1996;157:126-137.
82. Gollob JA, et al. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol 1999;162:4472-4481.
83. Moriggl R, et al. Activation of STAT proteins and cytokine genes in human Th 1 and Th2 cells generated in the absence of IL-12 and IL-4. J Immunol 1998;160:3385-3392.
84. + T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci USA 2003;100:15047-15052.
85. Wang KS, Ritz J, Frank DA. IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol 1999;162:299-304.
86. Strengell M, et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 2003;170:5464-5469.
87. Cho SS, et al. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 1996;157:4781-4789.
88. Rogge L, et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 1998;161:6567-6574.
89. Sinigaglia F, D'Ambrosio D, Rogge L. Type I interferons and the Th1/Th2 paradigm. Dev Comp Immunol 1999;23:657-663.
90. Nguyen KB, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002;297:2063-2066.
91. Freudenberg MA, et al. Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling. J Immunol 2002;169:1665-1668.
92. Wang J, et al. Dysregulated sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain. J Clin Invest 2003;112:535-543.
93. Pignata C, et al. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol 1995;165:211-216.
94. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72.
95. Zhang S, Kaplan MH. The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression. J Immunol 2000;165:1374-1380.
96. Rincon M, et al. Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 1998;17:2817-2829.
97. Lu HT, et al. Defective IL-12 production in mitogen-activated protein (MAP) kinase 3 (Mkk3)-deficient mice. EMBO J 1999;18:1845-1857.
98. Yang J, et al. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat Immunol 2001;2:157-164.
99. Lu B, et al. GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity 2001;14:583-590.
100. Li B, et al. Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation. Science 2000;288:2219-2222.
101. Dong Z, et al. Activation of cytokine production, tumoricidal properties, and tyrosine phosphorylation of MAPKs in human monocytes by a new synthetic lipopeptide, JBT3002. J Leukoc Biol 1998;63:766-774.
102. + T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998;9:575-585.
103. Brennan P, et al. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 1997;7:679-689.
104. Athie MV, et al. IL-12 selectively regulates STAT4 via phosphatidylinositol 3-kinase and Ras-independent signal transduction pathways. Eur J Immunol 2000;30:1425-1434.
105. + T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 2002;169:3637-3643.
106. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 2002;277:25851-25854.
107. Yoshimoto T, et al. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor beta 1 cytoplasmic region. J Immunol 2003;171:1352-1359.
108. Liu F, et al. Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G (ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol 2001;24:711-719.
109. Osawa Y, et al. TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J Immunol 2001;167:173-180.
110. Igarashi J, Michel T. Sphingosine 1-phosphate and isoform-specific activation of phosphoinositide 3-kinase beta. Evidence for divergence and convergence of receptor-regulated endothelial nitric-oxide synthase signaling pathways. J Biol Chem 2001;276:36281-36288.
111. Diefenbach A, et al. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity (erratum appears in Science 1999;284:1776) Science 1999;284:951-955.
112. Diefenbach A, et al. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity (erratum appears in Science 1999;284:1776) Science 1999;284:951-955.
113. Chin AI, et al. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 2002;416:190-194.
114. Al-Mohanna F, et al. IL-12-dependent nuclear factor-kappaB activation leads to de novo synthesis and release of IL-8 and TNF-alpha in human neutrophils. J Leukoc Biol 2002;72:995-1002.
115. Tato CM, et al. Inhibition of NF-kappa B activity in T and NK cells results in defective effector cell expansion and production of IFN-gamma required for resistance to Toxoplasma gondii. J Immunol 2003;170:3139-3146.
116. Alexander WS, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
117. Eyles JL, et al. Negative regulation of interleukin-12 signaling by suppressor of cytokine signaling-1. J Biol Chem 2002;277:43735-43740.
118. Yamamoto K, et al. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun 2003;310:1188-1193.
119. Seki Y, et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 2003;9:1047-1054.
120. Matsumoto A, et al. A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. J Exp Med 2003;197:425-436.
121. Yu CR, et al. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem 2003;278:29752-29759.
122. Anderson P, et al. Differential activation of signal transducer and activator of transcription (STAT) 3 and STATS and induction of suppressors of cytokine signalling in Th1 and Th2 cells. Int Immunol 2003;15:1309-1317.
123. Lovato P, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003;278:16777-16781.
124. Lang R, et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 2003;4:546-550.
125. Croker BA, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003;4:540-545.
126. Yasukawa H, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 2003;4:551-556.
127. Schmidt D, Muller S. PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 2003;60:2561-2574.
128. Wormald S, Hilton DJ. Inhibitors of cytokine signal transduction. J Biol Chem 2004;279:821-824.
129. Arora T, et al. PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4. J Biol Chem 2003;278:21327-21330.
130. Wang KS, Zorn E, Ritz J. Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. Blood 2001;97:3860-3866.
131. Micallef MJ, et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996;26:1647-1651.
132. Robinson D, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997;7:571-581.
133. Lauwerys BR, Renauld JC, Houssiau FA. Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 1999;11:822-830.
134. Yoshimoto T, et al. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 1997;94:3948-3953.
135. Fukao T, et al. Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol 2001;166:4446-4455.
136. Lawless VA, et al. Stat4 regulates multiple components of IFN-gamma-inducing signaling pathways. J Immunol 2000;165:6803-6808.
137. Dong C, Flavell RA. Th1 and Th2 cells. Curr Opin Hematol 2001;8:47-51.
138. Glimcher LH. Lineage commitment in lymphocytes: controlling the immune response. J Clin Invest 2001;108:s25-s30.
139. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109: S121-S131.
140. O'Shea JJ, Paul WE. Regulation of T(H)1 differentiation controlling the controllers. Nat Immunol 2002;3:506-508.
141. Farrar JD, Asnagli H, Murphy KN. T helper subset development: roles of instruction, selection, and transcription. J Clin Invest 2002;109:431-435.
142. Ho IC, Glimcher LH. Transcription: tantalizing times for T cells. Cell 2002;109:S109-S120.
143. Aggarwal S, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-1914.
144. Mattner F, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-1559.
145. Magram J, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996;4:471-481.
146. Wu C, et al. Characterization of IL-12 receptor beta1 chain (IL-12Rbeta1)-deficient mice: IL-12Rbeta1 is an essential component of the functional mouse IL-12 receptor. J Immunol 1997;159:1658-1665.
147. Wu CY, et al. Cytokine regulation of IL-12 receptor beta2 expression: differential effects on human T and NK cells. Eur J Immunol 2000;30:1364-1374.
148. Decken K, et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Gyptococcus neoformons. Infect Immun 1998;66:4994-5000.
149. Piccotti JR, et al. Alloantigen-reactive Th1 development in IL-12-deficient mice. J Immunol 1998;160:1132-1138.
150. Camoglio L, et al. Contrasting roles of IL-12 p40 and IL-12p35 in the development of hapten-induced colitis. Eur J Immunol 2002;32:261-269.
151. Frucht DM. IL-23: a cytokine that acts on memory T cells. Sci STKE 2002;2002:PE1.
152. Cua DJ, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-748.
153. Murphy CA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-1957.
154. Ghilardi N, et al. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004;172:2827-2833.
155. Thierfelder WE, et al. Requirement for Stat4 in interleukin-12-mediaied responses of natural killer and T cells. Nature 1996;382:171-174.
156. Kaplan MH, et al. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996;382:174-177.
157. Kaplan MH, Wurster AL, Grusby MJ. A signal transducer and activator of transcription (Stat) 4-independent pathway for the development of T helper type 1 cells. J Exp Med 1998;188:1191-1196.
158. Sugawara I, Yamada H, Mizuno S. Relative importance of STAT4 in murine tuberculosis. J Med Microbiol 2003;52:29-34.
159. Aguilar-Delfin I, Wettstein PJ, Persing DH. Resistance to acute babesiosis is associated with imerleukin-12- and gamma interferon-mediated responses and requires macrophages and natural killer cells. Infect Immun 2003;71:2002-2008.
160. Stamm LM, et al. STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol 1999;29:2524-2529.
161. Buxbaum LU, et al. Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent. Eur J Immunol 2002;32:3206-3215.
162. Cai G, et al. Identification of STAT4-dependent and independent mechanisms of resistance to Toxoplosma gondii. J Immunol 2000;165:2619-2627.
163. Tarleton RL, Grusby MJ, Zhang L. Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deftcient mice to infection with Trypanosoma cruzi. J Immunol 2000;165:1520-1525.
164. Matsukawa A, et al. Pivotal role of signal transducer and activator of transcription (Stat) 4 and Stat6 in the innate immune response during sepsis. J Exp Med 2001;193:679-688.
165. Godshall CJ, et al. STAT4 is required for antibacterial defense but enhances mortality during polymicrobial sepsis. Clin Diagn Lab Immunol 2001;8:1044-1048.
166. + T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism [erratum appears in J Immunol 2003;170:4411. Note: Chtinis T corrected to Chitnis]. J Immunol 2003;170:1958-1963.
167. + T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism [erratum appears in J Immunol 2003;170:4411. Note: Chtinis T corrected to Chitnis]. J Immunol 2003;170:1958-1963.
168. Scott MJ, Godshall CJ, Cheadle WG. Jaks, STATS, cytokines, and sepsis. Clin Diagn Lab Immunol 2002;9:1153-1159.
169. Lentsch AB, et al. STAT4 and STAT6 regulate systemic inflammation and protect against lethal endotoxemia. J Clin Invest 2001;108:1475-1482.
170. Toshchakov V, et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 2002;3:392-398.
171. Doughty L, et al. A role for IFN-alpha beta in virus infection-induced sensitization to endotoxin. J Immunol 2001;166:2658-2664.
172. Holz A, et al. Disruption of the STAT4 signaling pathway protects from autoimmune diabetes while retaining antiviral immune competence. J Immunol 1999;163:5374-5382.
173. Finnegan A, et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002;169:3345-3352.
174. Chitnis T, et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001;108:739-747.
175. Afanasyeva M, et al. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma- independent pathway. Circulation 2001;104:3145-3151.
176. -/- BALB/c mice suggests a pathogenic role of Th1 cells. J Immunol 2004;172:97-103.
177. Simpson SJ, et al. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on Interferon gamma expression by T cells. J Exp Med 1998;187:1225-1234.
178. + T cells that respond to bacterial antigens. J Immunol 1999;162:1884-1888.
179. Jacob CO, et al. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 2003;171:1564-1571.
180. Singh RR, et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003;170:4818-4825.
181. Raman K, et al. STAT4 signal pathways regulate inflammation and airway physiology changes in allergic airway inflammation locally via alteration of chemokines. J Immunol 2003;170:3859-3865.
182. Zhou P, et al. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 2000;165:5580-5587.
183. Chiang PH, et al. Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J Immunol 2004;172:1355-1363.
184. Nikolic B, et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000;105:1289-1298.
185. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002;20:581-620.
186. Picard C, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 2002;70:336-348.
187. Fieschi C, Casanova JL. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol 2003;33:1461-1464.
188. Hoeve MA, et al. IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor beta1 deficiency. Eur J Immunol 2003;33:3393-3397.
189. Kondo N, et al. Atopy and mutations of IL-12 receptor beta 2 chain gene. Clin Exp Allergy 2001;31:1189-1193.
190. Matsui E, et al. Mutations of the IL-12 receptor beta2 chain gene in atopic subjects. Biochem Biophys Res Commun 1999;266:551-555.
191. Toyoda H, et al. Impairment of IL-12-dependent STAT4 nuclear translocation in a patient with recurrent Mycobacterium ovium infection. J Immunol 2004;172:3905-3912.
192. Xu X, Sun YL, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 1996;273:794-797.
193. Zhang F, Nakamura T, Aune TM. TCR and IL-12 receptor signals cooperate to activate an individual response element in the IFN-gamma promoter in effector Th cells. J Immunol 1999;163:728-735.
194. Nakahira M, et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 2002;168:1146-1153.
195. + T lymphocytes. J Immunol 1998;160:3642-3647.
196. Murphy KM, Reiner SL. Decision making in the immune system: The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-944.
197. Agnello D, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003;23:147-161.
198. Avni O, et al. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002;10:10.
199. Fields PE, Kim ST, Flavell RA. Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. J Immunol 2002;169:647-650.
200. Grogan JL, et al. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 2001;14:205-215.
201. Szabo SJ, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
202. Mullen AC, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001;292:1907-1910.
203. Szabo SJ, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CDS T cells. Science 2002;295:338-342.
204. Bream JH, et al. IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-gamma expression in murine NK cells. Blood 2003;102:207-214.
205. Lee DU, et al. A distal enhancer in the interferon-gamma (IFN-gamma) locus revealed by genome sequence comparison. J Biol Chem 2004;279:4802-4810.
206. O'Sullivan A, et al. STAT4 is required for interleukin-12-induced chromatin remodeling of the CD25 locus. J Biol Chem 2004;279:7339-7345.
207. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 2003;9:1107-1113.
208. Schmidt C, et al. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology 2002;70:177-183.
209. Changelian PS, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-888.
210. Velazquez L, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992;70:313-322.
211. Shimoda K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13:561-571.
212. Schleicher U, et al. Control of Leishmania major in the absence of Tyk2 kinase. Eur J Immunol 2004;34:519-529.
213. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-644.
214. Ortmann R, et al. A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J Immunol 2001;166:5712-5719.
215. Yap GS, et al. A heritable defect in IL-12 signaling in B10.Q/J mice. II. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J Immunol 2001;166:5720-5725.
216. Shaw MH, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003;100:11594-11599.
217. Greenlund AC, et al. Ligand-induced IFN gamma receptor tyrosine phosphorylation couples the receptor to its signal transduction system (p91). EMBO J 1994;13:1591-1600.
218. Schindler U, et al. Components of a Stat recognition code: evidence for two layers of molecular selectivity. Immunity 1995;2:689-697.
219. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
220. Turkson J, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004;3:261-269.
221. Leong PL, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;100:4138-4143.
222. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001;12:143-156.
223. Palosaari H, et al. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J Virol 2003;77:7635-7644.
224. Ulane CM, et al. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol 2003;77:6385-6393.
225. Rodriguez JJ, Parisien JP, Horvath CM. Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol 2002;76:11476-11483.
226. Parisien JP, et al. Selective STAT protein degradation induced by paramyxoviruses requires both STAT1 and STAT2 but is independent of alpha/beta interferon signal transduction. J Virol 2002;76:4190-4198.
227. Parisien JP, et al. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 2001;283:230-239.
228. Youssef S, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
229. Nath N, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004;172:1273-1286.
230. Leung BP, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-1530.
231. Vollmer T, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608.
232. Monick MM, et al. Intracellular thiols contribute to Th2 function via a positive role in IL-4 production. J Immunol 2003;171:5107-5115.
233. Coon ME, et al. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol 1999;163:6567-6574.
234. Yang Z, et al. Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci 2003;1005:409-411.
235. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002;168:6506-6513.
236. Chan SH, et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991;173:869-879.
237. Gately MK, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 1994;6:157-167.
238. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000;19:2577-2584.
239. Seder RA, et al. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med 1995;182:1067-1077.
240. Gerosa F, et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 1996;183:2559-2569.
241. + thymocytes into functionally mature Th2 cells. Exogenous interleukin-12 is required for priming thymocytes to produce both Th1 cytokines and interleukin-10. Eur J Immunol 1996;26:1083-1087.
242. Galon J, et al. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol 1999;162:7256-7262.
243. Matikainen S, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999;93:1980-1991.
244. Valenzuela J, Schmidt C, Mescher M. The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 2002;169:6842-6849.
245. Yoshimoto T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998;161:3400-3407.
246. Nakahira M, et al. An absolute requirement for STAT4 and a role for IFN-gamma as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. J Immunol 2001;167:1306-1312.
247. Cesano A, et al. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J Immunol 1993;151:2943-2957.
248. Aste-Amezaga M, et al. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 1994;156:480-492.
249. Orange JS, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995;181:901-914.
250. Schindler U, Hoey T, McKnight SL. Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Genes Cells 1996;1:507-515.
251. Angiolillo AL, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 1996;795:158-167.
252. Kanegane C, et al. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol 1998;64:384-392.
253. Rogge L, et al. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 2000;25:96-101.
254. Bonecchi R, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-134.
255. + T cells are associated with IFN-gamma production. FASEB J 1996;10:769-776.
256. Lim YC, et al. IL-12, STAT4-dependent upregulation of CD4(+) T cell core 2 beta-1, 6-n-acetylglucosaminyltransferase, an enzyme essential for biosynthesis of P-selectin ligands. J Immunol 2001;167:4476-4484.
257. White SJ, et al. Cutting edge: differential requirements for Stat4 in expression of glycosyltransferases responsible for selectin ligand formation in Th1 cells. J Immunol 2001;167:628-631.
258. Azzoni L, et al. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol 1998;161:3493-3500.
259. + T cells: reversal by interleukin-12 stimulation. Blood 2003;101:3543-3549.
260. Yamabe T, et al. Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. Immunology 1997;91:151-158.
261. Hamalainen H, Meissner S, Lahesmaa R. Signaling lymphocytic activation molecule (SLAM) is differentially expressed in human Th1 and Th2 cells. J Immunol Methods 2000;242:9-19.
262. Ouyang W, et al. The Ets transcription factor ERM is Th1-specific and induced by IL-12 through a Stat4-dependent pathway. Proc Natl Acad Sci USA 1999;96:3888-3893.
263. Coccia EM, et al. Interleukin-12 induces expression of interferon regulatory factor-1 via signal transducer and activator of transcription-4 in human T helper type 1 cells. J Biol Chem 1999;274:6698-6703.
264. Lehtonen A, et al. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 2003;24:81-90.
265. Yamamoto K, et al. The human perform gene is a direct target of STAT4 activated by IL-12 in NK cells. Biochem Biophys Res Commun 2002;297:1245-1252.
266. Morinobu A, Kanno Y, O'shea JJ. Discreate roles for histone acetylation in human T helper 1 cell-specific gene expression. J Biol Chem 2004;279:40640-40646.
267. Bream JH, et al. A distal region in the IFN-gamma gene is a site of epigenetic remodeling and transcriptional regulation by IL-2. J Biol Chem 2004;279:41249-41257.